Physician profile
Alex Limanni
NPI 1477585974
$1,524.35
in general payments reported to CMS, 2019-2025
18 companies · $72.25 in 2025
The $72.25 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,329 · 2020: $46.88 · 2023: $75.78 · 2025: $72.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $148.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $359.74 | 2019 | |
| Amgen INC. | $271.20 | 2019 | |
| Novartis Pharmaceuticals Corporation | $149.81 | 2019 | |
| Glaxosmithkline, LLC. | $117.98 | 2019-2023 | Benlysta |
| Genzyme Corporation | $83.80 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $72.25 | 2025 | Saphnelo |
| Sanofi-Aventis U.S. LLC | $69.31 | 2019 | |
| Pfizer INC. | $64.18 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $58.77 | 2019 | |
| Celgene Corporation | $52.72 | 2019 | |
| Ucb, INC. | $42.82 | 2019 | |
| Lilly USA, LLC | $35.88 | 2019 | |
| Sandoz INC. | $35.00 | 2020 | |
| Mallinckrodt Enterprises LLC | $31.85 | 2019 | |
| Medexus Pharma, INC. | $25.00 | 2019-2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $19.32 | 2019 | |
| Janssen Biotech, INC. | $18.77 | 2019 | |
| Horizon Therapeutics Plc | $15.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Limanni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.